Clinical trial
Assessment of Clinical Practice Administration of Chemotherapy and Anti-angiogenic Agent (Bevacizumab) Retrospectively and Prospectively as First Line Treatment for Patients With Advanced or Metastatic Non Small Cell Lung Cancer. Assessment of Toxicity, Compliance and Survival of Patients.
NCT01934465 is registered in ClinicalTrials.gov with Hellenic Oncology Research Group as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Assessment of Clinical Practice Administration of Chemotherapy and Anti-angiogenic Agent (Bevacizumab) Retrospectively and Prospectively as First Line Treatment for Patients With Advanced or Metastatic Non Small Cell Lung Cancer. Assessment of Toxicity, Compliance and Survival of Patients.
- Lead sponsor
- Hellenic Oncology Research Group
- Phase
- Observational
- Overall status
- Completed
- Start date
- February 28, 2010
- Completion date
- December 31, 2013
- Enrollment
- 300 (actual)
- Sites
- 8
Conditions
As the registry lists them; a condition with its own page is linked.
non small cell lung cancer